CONDYLOX (podofilox) by Teva is mechanism of action treatment of anogenital warts with podofilox results in necrosis of visible wart tissue. Approved for the treatment of mucous membrane warts (see ). First approved in 1990.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CONDYLOX (podofilox) is a topical solution indicated for treatment of anogenital warts (mucous membrane warts) approved in 1990. The drug works by inducing necrosis of visible wart tissue, though the exact molecular mechanism remains unknown. It is a small molecule therapeutic applied directly to affected tissue.
LOE-approaching product with minimal Part D spending ($17K) indicates small, stable team focused on managed decline and generic transition support.
Mechanism of Action Treatment of anogenital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown.
CONDYLOX represents a mature, low-activity asset with zero linked job openings, indicating minimal hiring and career mobility. Working on this product offers limited growth potential but stable compliance and customer service responsibilities in a declining market.
Worked on CONDYLOX at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo